Paolo Pertile
Names
| first: |
Paolo |
| last: |
Pertile |
Identifer
Contact
Affiliations
-
Università degli Studi di Verona
/ Facoltà di Economia
/ Dipartimento di Scienze Economiche
Research profile
author of:
- Dynamic, incentive-compatible contracting for health services (RePEc:ags:feemwp:338404)
by Levaggi, Rosella & Moretto, Michele & Pertile, Paolo - Optimal Bayesian sequential sampling rules for the economic evaluation of health technologies (RePEc:bla:jorssa:v:177:y:2014:i:2:p:419-438)
by Paolo Pertile & Martin Forster & Davide La Torre - A Bayesian decision theoretic model of sequential experimentation with delayed response (RePEc:bla:jorssb:v:79:y:2017:i:5:p:1439-1462)
by Stephen Chick & Martin Forster & Paolo Pertile - Investment in Health Technologies in a Competitive Model with Real Options (RePEc:bla:jpbect:v:10:y:2008:i:5:p:923-952)
by Paolo Pertile - The Dynamics of Pharmaceutical Regulation and R&D Investments (RePEc:bla:jpbect:v:19:y:2017:i:1:p:121-141)
by Rosella Levaggi & Michele Moretto & Paolo Pertile - Two-part payments for the reimbursement of investments in health technologies (RePEc:eee:hepoli:v:115:y:2014:i:2:p:230-236)
by Levaggi, Rosella & Moretto, Michele & Pertile, Paolo - Static and dynamic efficiency of irreversible health care investments under alternative payment rules (RePEc:eee:jhecon:v:31:y:2012:i:1:p:169-179)
by Levaggi, R. & Moretto, M. & Pertile, P. - Late-stage pharmaceutical R&D and pricing policies under two-stage regulation (RePEc:eee:jhecon:v:50:y:2016:i:c:p:298-311)
by Jobjörnsson, Sebastian & Forster, Martin & Pertile, Paolo & Burman, Carl-Fredrik - R&D and market size: Who benefits from orphan drug legislation? (RePEc:eee:jhecon:v:80:y:2021:i:c:s0167629621001077)
by Gamba, Simona & Magazzini, Laura & Pertile, Paolo - A large scale OLG model for the analysis of the redistributive effects of policy reforms (RePEc:eee:poleco:v:48:y:2017:i:c:p:104-127)
by Bucciol, Alessandro & Cavalli, Laura & Fedotenkov, Igor & Pertile, Paolo & Polin, Veronica & Sartor, Nicola & Sommacal, Alessandro - Technology adoption, quality and health care costs: a review of the literature (RePEc:fan:steste:v:html10.3280/ste2006-090005)
by Paolo Pertile - Static and Dynamic Efficiency of Irreversible Health Care Investments under Alternative Payment Rules (RePEc:fem:femwpa:2010.130)
by Rosella Levaggi & Michele Moretto & Paolo Pertile - Dynamic, incentive-compatible contracting for health services (RePEc:fem:femwpa:2023.16)
by Rosella Levaggi & Michele Moretto & Paolo Pertile - The timing of adoption of positron emission tomography: a real options approach (RePEc:kap:hcarem:v:12:y:2009:i:3:p:217-227)
by Paolo Pertile & Emanuele Torri & Luciano Flor & Stefano Tardivo - An extension of the real option approach to the evaluation of health care technologies: the case of positron emission tomography (RePEc:kap:ijhcfe:v:9:y:2009:i:3:p:317-332)
by Paolo Pertile - The fiscal disadvantage of young Italians: a new view on consolidation and fairness (RePEc:kap:jecinq:v:13:y:2015:i:1:p:27-51)
by Paolo Pertile & Veronica Polin & Pietro Rizza & Marzia Romanelli - Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition (RePEc:spr:aphecp:v:18:y:2020:i:3:d:10.1007_s40258-019-00541-z)
by Rosella Levaggi & Paolo Pertile - Authors’ Reply to Garattini and Freemantle: “Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition” (RePEc:spr:aphecp:v:18:y:2020:i:3:d:10.1007_s40258-020-00557-w)
by Rosella Levaggi & Paolo Pertile - Redistribution at the local level: the case of public childcare in Italy (RePEc:spr:inrvec:v:63:y:2016:i:4:d:10.1007_s12232-016-0258-z)
by Alessandro Bucciol & Laura Cavalli & Paolo Pertile & Veronica Polin & Alessandro Sommacal - Dynamic, economic approaches to HTA under uncertainty (RePEc:ver:wpaper:03/2011)
by Martin Forster & Paolo Pertile - Public finance consolidation and fairness across living generations: the case of Italy (RePEc:ver:wpaper:04/2012)
by Paolo Pertile & Veronica Polin & Pietro Rizza & Marzia Romanelli - L’ISEE in Italia: Una Nota Metodologica Partendo dai Dati IT-SILC (RePEc:ver:wpaper:06/2014)
by Alessandro Bucciol & Laura Cavalli & Elena Dalla Chiara & Martina Menon & Paolo Pertile & Veronica Polin & Alessandro Sommacal - R&D and market size: who benefits from orphan drug regulation? (RePEc:ver:wpaper:09/2019)
by Simona Gamba & Laura Magazzini & Paolo Pertile - The dynamics of pharmaceutical regulation and R&D investments (RePEc:ver:wpaper:13/2013)
by Rosella Levaggi & Michele Moretto & Paolo Pertile - Pricing policies when patients are heterogeneous: a welfare analysis (RePEc:ver:wpaper:17/2016)
by Rosella Levaggi & Paolo Pertile - Who should monitor job sick leave? (RePEc:ver:wpaper:18/2015)
by Carlo Alberto Biscardo & Alessandro Bucciol & Paolo Pertile - Redistribution at the Local Level: The Case of Public Childcare in Italy (RePEc:ver:wpaper:21/2013)
by Alessandro Bucciol & Laura Cavalli & Paolo Pertile & Veronica Polin & Alessandro Sommacal - Modelling life-course decisions for the analysis of interpersonal and intrapersonal redistribution (RePEc:ver:wpaper:25/2012)
by Laura Cavalli & Alessandro Bucciol & Paolo Pertile & Veronica Polin & Nicola Sartor & Alessandro Sommacal - Public policies over the life cycle: a large scale OLG model for France, Italy and Sweden (RePEc:ver:wpaper:29/2015)
by Alessandro Bucciol & Laura Cavalli & Igor Fedotenkov & Paolo Pertile & Veronica Polin & Nicola Sartor & Alessandro Sommacal - DRGs: the link between investment in technologies and appropriateness (RePEc:ver:wpaper:31/2012)
by Rosella Levaggi & Michele Moretto & Paolo Pertile - Optimal decision rules for HTA under uncertainty: a wider, dynamic perspective (RePEc:wly:hlthec:v:22:y:2013:i:12:p:1507-1514)
by Martin Forster & Paolo Pertile - Job sick leave: Detecting opportunistic behavior (RePEc:wly:hlthec:v:28:y:2019:i:3:p:373-386)
by Carlo Alberto Biscardo & Alessandro Bucciol & Paolo Pertile - Which valued‐based price when patients are heterogeneous? (RePEc:wly:hlthec:v:29:y:2020:i:8:p:923-935)
by Rosella Levaggi & Paolo Pertile - The impact of managed entry agreements on pharmaceutical prices (RePEc:wly:hlthec:v:29:y:2020:i:s1:p:47-62)
by Simona Gamba & Paolo Pertile & Sabine Vogler - A reply to “Who would benefit from average value‐based pricing?” (RePEc:wly:hlthec:v:30:y:2021:i:9:p:2284-2286)
by Rosella Levaggi & Paolo Pertile - Spillovers of Pharmaceutical Price Regulations: evidence from the AMNOG Reform in Germany (RePEc:yor:hectdg:22/20)
by Gamba, S.; & Pertile, P.; & Righetti, G.; - Optimal sequential sampling rules for the economic evaluation of health technologies (RePEc:yor:yorken:10/24)
by Paolo Pertile & Martin Forster & Davide La Torre - A Bayesian Decision-Theoretic Model of Sequential Experimentation with Delayed Response (RePEc:yor:yorken:15/09)
by Stephen Chick & Martin Forster & Paolo Pertile - Late-Stage Pharmaceutical R & D and Pricing Policies under Two-Stage Regulation (RePEc:yor:yorken:15/16)
by Sebastian Jobjornsson & Martin Forster & Paolo Pertile & Carl-Fredrik Burman - Free-Riding in Pharmaceutical Price Regulation: Theory and Evidence (RePEc:yor:yorken:18/04)
by Paolo Pertile & Simona Gamba & Martin Forster